Key facts
- This page summarizes Jason Campagna's Form 4 filing for Q32 Bio Inc. (QTTB).
- 7 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 26 Feb 2025, 21:57.
Jason Campagna - 24 Feb 2025 Form 4 Insider Report for Q32 Bio Inc. (QTTB)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- QTTB
- Reported as of
- 24 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2025, 21:57:04 UTC
- Prior SEC filing
- 27 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Bell, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jason Campagna filed Form 4 for Q32 Bio Inc. (QTTB) on 26 Feb 2025.
Change
- Previous filing in this sequence was filed on 27 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QTTB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +37,500
- Change %
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 24 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QTTB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -87,738
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,738
- Exercise price
- $7.29
- Footnotes
- F2, F3
QTTB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +87,738
- Change %
- Price
- $0.000000
- Shares after
- 87,738
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,738
- Exercise price
- $2.54
- Footnotes
- F2, F3, F4
QTTB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -17,951
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,951
- Exercise price
- $7.29
- Footnotes
- F2, F3
QTTB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +17,951
- Change %
- Price
- $0.000000
- Shares after
- 17,951
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,951
- Exercise price
- $2.54
- Footnotes
- F2, F3, F4
QTTB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -70,687
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 70,687
- Exercise price
- $16.82
- Footnotes
- F2, F3
QTTB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +70,687
- Change %
- Price
- $0.000000
- Shares after
- 70,687
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 70,687
- Exercise price
- $2.54
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
Footnote F2
On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
Footnote F3
This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Footnote F4
The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.